Ann Hoeben

Learn More
——Angiogenesis is a hallmark of wound healing, the menstrual cycle, cancer, and various isch-emic and inflammatory diseases. A rich variety of pro-and antiangiogenic molecules have already been discovered. Vascular endothelial growth factor (VEGF) is an interesting inducer of angiogenesis and lym-phangiogenesis, because it is a highly specific mitogen for(More)
Advanced and metastatic renal cell cancer (RCC) is resistant to conventional chemotherapy. Only a very small number of patients survive long term after immunotherapy. However, any effect of interleukin-2 (IL-2) and/or interferon on median overall survival is small, and treatment-associated toxicities may be severe. The disease is therefore an area of high(More)
The management of localised and advanced gastrointestinal stromal tumours (GISTs) in terms of histological diagnosis, surgery, imaging, medical treatment and molecular biology has rapidly changed since introduction of imatinib mesylate for molecularly targeted therapy in 2000. In this minireview, we briefly summarise and discuss the current data relevant to(More)
BACKGROUND There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. METHODS All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. RESULTS We identified a total of 77 patients(More)
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced head and neck squamous cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumor accessibility is an important factor in treatment success of the EGFR targeting drug. We quantified uptake of cetuximab labeled with Zirconium-89 (89Zr) using PET/CT(More)
  • 1